National asthma observational survey of severe asthmatics in Israel: the no-air study
© Izbicki et al.; licensee BioMed Central Ltd. 2012
Received: 1 March 2012
Accepted: 1 June 2012
Published: 1 June 2012
Asthma is considered a global public health issue requiring a significant medical expenditure as a result of its high prevalence and the low rate of disease control.
This is the first nationwide survey of severe asthma patients carried out in Israel. In this study we aimed to assess health resources utilization, compliance with treatment and disease-control in a subgroup of patients with severe asthma in Israel.
Material and method
One hundred and twenty-three patients with a diagnosis of asthma for more then one year, as well as a hospitalization during the last 12 months due to asthma exacerbation or maintenance systemic steroids therapy, were included in this non-interventional observational study.
Asthma was uncontrolled in 43.9%, partly controlled in 50.4% and well controlled in only 5.7%. The majority of the patients (83%) were compliant with drug treatment.
The fact that 83% of the asthma patients included in this study were compliant with their asthma therapy was not manifested in asthma control. Therefore concrete tools are required for achieving and maintaining asthma control, especially in the treatment of the most severe asthmatic patients.
Asthma represents a major public health concern, with increasing incidence and prevalence worldwide . Asthma affects over 300 million people all over the world and is one of the most common chronic diseases [2, 3]. Estimates of the prevalence of asthma range from 7% in France and Germany, to 11% in the USA and 15-18% in the United Kingdom . Approximately 20% of these patients have severe asthma, of which 20% are inadequately controlled ), and these patients are at particularly high risk of exacerbation, hospitalization and demise often suffering from a radically impaired quality of life. The medical expenditure related to asthma deriving from work absences, missed school days and increasing healthcare costs has raised this disease to high priority in terms of finding new therapeutic as well as improved compliance modalities.
Various studies indicate that the burden of illness is not necessarily associated with asthma itself but with the lack of asthma control . The unfavorable effects of inadequate asthma control range from increased risk of exacerbation and emergency visits, to hospitalization and death [6, 7].
The aim of this survey was to assess health resources utilization, compliance with treatment and disease-control in a subgroup of patients with severe asthma in Israel.
Material and methods
Study population and procedures
This is a non-interventional observational study based on a single patient visit conducted in 12 Israeli centers by pulmonologists, all members of the Israeli Pulmonary Society. The patients completed Hebrew-translated standard, international used questionnaires regarding asthma control, therapy compliance and quality of life, and the pulmonologists completed questionnaires with regard to severity, disease-control, comorbidities and treatment. More specifically, questionnaires were divided into five parts: 1) demographics 2) health resource utilization 3) compliance to treatment based on the standard Asthma Compliance Test , 4) level of asthma-control based on the standard Asthma Control Test ) and 5) asthma history and treatment. The first 3 parts were completed by the patients and the last 2 parts by the physicians. Patient's questionnaires were self-administered and completed in the out-patient clinic waiting area while physicians completed their questionnaires just after the patient's visit.
Patients above the age of 18 were included in this study after signing informed consent. Inclusion criteria were a diagnosis of asthma (based on the ATS and GINA guidelines) for more then one year together with either a hospitalization during the last 12 months due to asthma exacerbation, or maintenance systemic steroids therapy for at least 50% of the year. Total IgE level from up to 12 months before visit 1 until one month after visit 1 was obtained. All patients fulfilling inclusion criteria were asked to participate in this survey, during a 12 month period of time. Asthmatic patients who were hospitalized for reasons other than asthma, or patients with a diagnosis of COPD, were excluded from this survey. Asthma-control was assessed for every patient according to the Global Initiative for Asthma (GINA) update of 2006 [10, 11].
This observational survey was performed according to the principles of Good Clinical Practice, the Helsinki Declaration, and national laws and regulations for clinical studies. This survey received extraordinary approval from the Israeli Ministry of Health which authorized the participation of all affiliated pulmonologists in this study based upon the approval of the Independent Ethics Committee of Kaplan Medical Center (Rehovot) and receipt of the patients’ written informed consent.
Demographics, socio-economic and medical history
Demographics – Socio-economic and medical history
Total Number of recruited patients
*Age median (range)
Completed high school
Living in urban areas
Asthma related information
Diagnosis of asthma below the age of 40
Food or drug allergy
#Positive Skin test/RAST
Exacerbations, Hospitalizations & Intubation
Median number of exacerbations within the last 12 month (0-25)
Median number of exacerbations over the past 5 years (0-100)
History of hospitalization in ICU and intubation
Ninety percent of the patients were treated with short-acting beta-2-agonists (mostly salbutamol/albuterol), 19.2% with long-acting beta-2-agonists (LABA) (formoterol preferred among other LABA), 15% inhaled corticosteroids (budesonide preferred), and 83.7% inhaled combination therapy (salmeterol/fluticasone preferred). Other drugs included montelukast (n = 37, 30%), theophylline (n = 29, 23.6%), and omalizumab (n = 26, 21.1%). No patient received LABA alone. The majority (68%) of the patients receiving LABA did so on-top of inhaled combination therapy while the rest (32%) were treated with separate LABA and inhaled corticosteroids. Amongst patients treated with inhaled combination therapy 87% received the maximal dose (salmeterol/fluticasone 500 mcg two times per day or formoterol/budesonide 320mcg two times per day and only 13% received a smaller dose (salmeterol/fluticasone 250 mcg two times per day or formoterol/budesonide 160mcg two times per day. Forty-three percent received corticosteroids systemically (prednisone preferred) as a maintenance therapy. The most common treatment-associated adverse events included osteoporosis, obesity, and hypertension.
Quality of life and compliance
Quality of Life: results expressed as median (range) or percentage of total
Visits to the ER
Hospitalizations within last 12 months
Hospitalizations in last 5 years
Duration of hospital stay
Working days lost due to asthma
Asthma attacks daily
Woke up 4 or more times a night per week
Compliance and asthma-control
Use steroids daily
Afraid/very afraid of side effects
Stated they were always compliant with treatment
Aware of the need for continuous treatment
Thought lack of compliance would have a negative impact on their disease
Thought treatment with tablets was more efficient than inhalation.
Denied the last statement
Stated asthma was partially or not-at-all controlled
Stated asthma was well controlled
This is the first nationwide survey undertaken in Israel concerning severe asthma patients. In this study we found that the majority of the patients (83%) were compliant with drug treatment. However this high self-declared compliance did not translate into asthma control. According to 2006 GINA assessment, 94.3% of patients had partially-controlled or uncontrolled asthma in this study. The median number of exacerbations within the last year was four. The results of this survey are based on questionnaires filled in by patients and physicians, and differ somewhat from the results of the telephone survey performed by Chapman et al.  in Canada, although both surveys confirmed the high prevalence of uncontrolled asthma. Forty-nine percent of all 123 patients stated that their asthma was not at all or only partially controlled. Forty-three percent of the patients did not answer this question, but taking into account other answers (i.e., 65% of patients stated they had daily asthma attacks) we can evaluate that the percentage of patients with partially or non-controlled asthma is very high. This assumption is also based on the fact that only 8.3% of the patients thought that their asthma was fully controlled. The pulmonologists found that only 5.7% of the patients had well-controlled asthma, which is quite consistent with the patients’ self-evaluation of well-controlled disease. In the Reality of Asthma Control (TRAC) study  53% of adults who reported having asthma were uncontrolled. In the INSPIRE study  51% of the patients had uncontrolled asthma, as assessed by the Asthma Control Questionnaire. Although study populations and methodology are very different in these two studies the percentage of uncontrolled asthma is quite similar. In 2009 Demoly et al. published a cross-sectional study of 37,476 adults in France, Germany, Italy, Spain and the UK in which 50.4% of asthma patients reported having partially-controlled disease . Severe persistent asthma causes a substantial morbidity and mortality burden and is frequently inadequately controlled despite intensive guideline-based therapy. The high percentage of patients with asthma under little or no control in our study is partially due to the extremely restrictive inclusion criteria of our survey. Nevertheless, according to GINA guidelines, asthma control can be achieved and maintained amongst the majority of asthmatics. In our study, although 83.7% of the patients used combination therapy (inhaled steroids and LABA) only 30% used montelukast and 21% omalizumab, despite the severity and poor control-level of their disease. Although there was a trend amongst better asthma control in the subgroup of patients treated with corticosteroids systemically or Omalizumab, this difference did not reached statistically significance as compared with the total population. As many as 83% of the patients reported constant compliance with their prescribed treatment. We had no possibility to reconcile the patient's reports concerning the high compliance to treatment, with prescriptions refills or other more objective measure. There are more objective methods to assess compliance with treatment but as this was a non-interventional, observational survey, we were limited to the use of questionnaires only. Although this information is based on patients report only, authors believe that there is room for improvement of current treatment regimens in the subset of patients presented in this study.
The limitations of this survey are firstly the small size of the study group. The relatively small size of the group can be explained by the restrictive inclusion criteria. It is not a general survey of asthma control in Israel but a survey of a severe asthmatic population. Moreover, as participation to this national survey was on a volunteer basis, not all the hospitals and pulmonologists, took an active part in this survey. Nevertheless we do think that this is a representative sample of the sub-population of patients with severe asthma. It should also be stressed that since there is no uniform definition of severe asthma, the results of this study are limited to the recruited population and not to all severe asthmatics. Secondly, we did not analyze the association of asthma control with other diseases, health attitudes (obesity, smoking,) or treatments. The third limitation is the use of the questionnaire to assess compliance with asthma medication. The patients' questionnaires were self-administered and completed. There are more objective methods to assess compliance but as this was a non-interventional survey we used validated questionnaires. Finally it might be argued that surveying patients in hospital facilities would be biased towards including mostly uncontrolled asthma patients since such patients are more likely to require care in a hospital setting.
In this survey, asthma impaired quality of life and was a major cause of hospitalizations, emergency room visits and absence from work/school. Although most patients surveyed in this study (83%) declared full treatment compliance, this overwhelming number did not translate into satisfactory disease control, as only 5.7 - 8.3% of the patients (physicians’ versus patients’ evaluation), claimed well controlled asthma. Several studies, including this survey, show that the illness burden is not only associated with the severity of the disease but mostly with the lack of asthma control. More concerted efforts in achieving and maintaining control are needed. Other treatment options for severe asthmatic patients should be considered since most of the severe patients were not well controlled.
List of centers participating in this trial who recruited more then 5 patients, Name of PI (and number of patients they recruited).
Kaplan Medical Center, Rehovot, Dr. G. Fink, (30).
Shaare Zedek Medical Center, Jerusalem, Dr. G. Izbicki (15)
Barzilai Medical Center, Ashkelon, Dr. Z. Weiler (11)
Macabi and Meuhedet Sick funds, Jerusalem, Dr. A. Grossman (11)
Sheba Medical Center, Tel-Hashomer, Prof. Y. Ben-Dov (10)
Hadassah Medical Center, Jerusalem, Prof. R. Breuer (10)
Assaf Harofeh Medical Center, Zrifin, Dr. D. Stav (8)
Hillel Yaffe Medical Center, Hadera, Dr. M. Bekerman (7)
Haemek Medical Center, Afula, Dr. M. Yunis (7)
Poria Medical Center, Tiberias, Dr. C. Sismolo (5)
Three other centers recruited a total of nine patients together.
This study was supported by an unrestricted grant from Novartis Israel to the Israeli Pulmonary Society. Novartis was not involved in the data acquisition, data analysis or drafting of the manuscript.
- Eder W, Ege MJ, von Mutius E: The asthma epidemic. N Engl J Med. 2006, 355: 2226-2235. 10.1056/NEJMra054308.View ArticlePubMedGoogle Scholar
- Demoly P, Paggiaro P, Plaza V: Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. Eur Respir Rev. 2009, 18: 105-112. 10.1183/09059180.00001209.View ArticlePubMedGoogle Scholar
- Pereg D, Tirosh A, Lishner M: Prevalence of asthma in a large group of Israeli adolescents: influence of country of birth and age at migration. Allergy. 2008, 63: 1040-1045. 10.1111/j.1398-9995.2008.01661.x.View ArticlePubMedGoogle Scholar
- Gaga M, Zervas E, Chanez P: Update on severe asthma: what we know and what we need. Eur Respir Rev. 2009, 18: 58-65. 10.1183/09059180.00001009.View ArticlePubMedGoogle Scholar
- Peters SP, Ferguson G, Deniz Y: Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 2006, 100: 1139-1151. 10.1016/j.rmed.2006.03.031.View ArticlePubMedGoogle Scholar
- Bousquet J, Clark TJ, Hurd S: GINA guidelines on asthma and beyond. Allergy. 2007, 62: 102-112.PubMedGoogle Scholar
- Chapman KR, Boulet LP, Rea RM: Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J. 2008, 31: 320-325. 10.1183/09031936.00039707.View ArticlePubMedGoogle Scholar
- Walewski KM, Cicutto L, D'Urzo AD: Evaluation of a questionnaire to assess compliance with anti-asthma medications. J Asthma. 2004, 41: 77-83. 10.1081/JAS-120026064.View ArticlePubMedGoogle Scholar
- Nathan RA, Sorkness CA, Kosinski M: Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004, 113: 59-65. 10.1016/j.jaci.2003.09.008.View ArticlePubMedGoogle Scholar
- The Global Initiative for Asthma (GINA). 2005,www.ginaasthma.com,
- The Global Initiative for Asthma (GINA) 2006 update. 2006,www.ginaasthma.com,
- FitzGerald JM, Boulet LP, Mclvor RA: Asthma control in Canada remains suboptimal: the Reality of Asthma Control (TRAC) study. Can Respir J. 2006, 13: 253-259.PubMed CentralPubMedGoogle Scholar
- Partridge MR, van der Molen T, Myrseth SE: Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006, 6: 13-10.1186/1471-2466-6-13.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.